Arora Reety, Gupta Komal, Vijaykumar Anjali, Krishna Sudhir
National Centre for Biological Sciences, Tata Institute of Fundamental Research (TIFR), Bangalore, India.
Department of Biology, Indian Institute of Science Education and Research, Pune, India.
Front Mol Biosci. 2020 Feb 4;7:10. doi: 10.3389/fmolb.2020.00010. eCollection 2020.
Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer caused either by Merkel cell polyomavirus (MCV) T antigen expression, post-integration (~80% cases), or by UV-mediated DNA damage. Interestingly, overall survival of MCV-positive Merkel cell carcinoma patients is better, making this differential information of significant diagnostic and prognostic value. Also, MCV provides a direct target for therapy in MCC patients. Currently, the methods used for diagnosis of MCV in tumors are often discordant and unreliable. Here we used a guided molecular scissors based-DNA Endonuclease Targeted CRISPR Trans Reporter (DETECTR) technique to develop an molecular diagnostic tool for MCV-positive MCC. DETECTR couples recombinase polymerase based amplification of target MCV DNA with Cas12a mediated detection. CRISPR diagnostics couple specific detection followed by cutting of the pathogenic DNA by the Cas enzyme-gRNA complex, with non-specific cutting of ssDNA that provides a measurable visual cue. To detect MCV DNA in MCC, we designed Cas12a gRNAs targeting the MCV DNA and tested their targeting efficiency, and sensitivity using a fluorophore quencher labeled reporter assay. We show that MCV DETECTR system can detect MCV integrated in Merkel tumor rapidly, specifically and with femto-molar sensitivity. Our study is a preliminary, proof-of-principle analysis showing the use of CRISPR for MCV diagnosis. Further validation in human tumor samples is needed for its clinical use in the near future. This new system is promising and we hope it can be coupled with immunohistochemical studies to diagnose the viral status of MCC in clinics soon.
默克尔细胞癌(MCC)是一种罕见的侵袭性皮肤癌,由默克尔细胞多瘤病毒(MCV)T抗原表达(整合后,约80%的病例)或紫外线介导的DNA损伤引起。有趣的是,MCV阳性默克尔细胞癌患者的总生存期更好,这使得这种差异信息具有重要的诊断和预后价值。此外,MCV为MCC患者提供了直接的治疗靶点。目前,用于肿瘤中MCV诊断的方法往往不一致且不可靠。在这里,我们使用基于引导分子剪刀的DNA内切酶靶向CRISPR转报告基因(DETECTR)技术开发了一种用于MCV阳性MCC的分子诊断工具。DETECTR将基于重组酶聚合酶的目标MCV DNA扩增与Cas12a介导的检测相结合。CRISPR诊断将特异性检测与Cas酶-gRNA复合物对致病DNA的切割相结合,同时对单链DNA进行非特异性切割,从而提供可测量的视觉线索。为了检测MCC中的MCV DNA,我们设计了靶向MCV DNA的Cas12a gRNA,并使用荧光团淬灭标记报告基因检测法测试了它们的靶向效率和灵敏度。我们表明,MCV DETECTR系统能够快速、特异性地检测整合在默克尔肿瘤中的MCV,灵敏度可达飞摩尔水平。我们的研究是一项初步的原理验证分析,展示了CRISPR在MCV诊断中的应用。在不久的将来,其临床应用还需要在人类肿瘤样本中进行进一步验证。这个新系统很有前景,我们希望它能很快与免疫组织化学研究相结合,用于临床诊断MCC的病毒状态。